Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 2, 2003, Pages 147-152

  Donadio, Michela ^a   Ardine, Mara ^a   Berruti, Alfredo ^b   Ritorto, Giuliana ^a   Fea, Elena ^a   Mistrangelo, Marinella ^a   Coccorullo, Zaira ^a   Bergnolo, Paola ^c   Comandone, Alessandro ^c   Bertetto, Oscar ^a  

^a MOLINETTE HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c GRADENIGO HOSPITAL   (Italy)

Author keywords

Gemcitabine; Metastatic breast cancer; Phase II; Second line treatment; Vinorelbine

Indexed keywords

ANTHRACYCLINE; GEMCITABINE; NAVELBINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOFT TISSUE METASTASIS; STOMATITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; VINBLASTINE;

EID: 0041876304     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0632-x     Document Type: Article

References (28)

1. Verdecchia A (1996) Survival in adult Italian cancer patients (1978-1989). ITACARE Working Group. Tumori 83:39-425
2. Hortobagyi GN (1994) Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 74 [1 Suppl 1]:416-423
3. Ellis MJ, Hayes DF, Lippman ME (2000) Treatment of metastatic breast cancer. In: Harris YR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the breast. Lippincott, Philadelphia, pp 749-787
4. Cardoso F, Di Leo A, Lohrisch C, Bernard C, Ferreira F, Piccart MJ (2002) Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 13:197-207
5. Fellous A, Ohayon R, Vacassin T, Binet S, Lataste H, Krikorian A, Couzinier JP, Meininger V (1989) Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 16 [Suppl 4]:9-14
6. Johnson SA, Harper P, Hortobagyi GN, Pouillart P (1996) Vinorelbine: an overview. Cancer Treat Rev 22:127-142
7. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G (1994) Vinorelbine is an active anti-proliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 12:2094-2101
8. Weber BL, Vogel C, Jones S, Harvey H, Hutchins L, Bigley J, Hohneker J (1995) Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer. J Clin Oncol 13:1245-1252
9. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A (1994) Vinorelbine (Navelbine) as salvage treatment for advanced breast cancer. Ann Oncol 5:423-426
10. Hertel LW, Kroin JS, Misner JW, Tustin JM (1988) Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2″-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406-2409
11. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Porre G, Todd GC, Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycitidine). Cancer Res 50:4417-4422
12. Luftner D, Flath B, Akrivakis C, Grunewald R, Mergenthaler HG, Possiger K (1998) Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124:527-531
13. Seidman AD (2001) The evolving role of gemcitabine in the management of breast cancer. Oncology 60:189-198
14. Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De Lena M (2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18:405-411
15. Krajnik G, Mohn-Staudner A, Thaler J, Greil R, Schmeikal S, Marhold F, Deutsch J, Preiss P, Malayari R, Schafer-Prokop C, Wein W, Huber H, Pirker R (2000) Vinorelbine-gemcitabine in advanced non-small cell lung cancer (NSCLC): an AASLC phase II trial. Ann Oncol 11:993-998
16. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C (1995) Paclitaxel by three-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
17. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D (1996) Lonidamine significantly increases the activity of epirubicin in advanced breast cancer patients: results from a multicenter prospective randomized trial. J Clin Oncol 14:1165-1172
18. Haider K, Kornek GV, Kwasny W, Weinlander G, Valencak J, Lang F, Puribauer F, Kovats E, Depisch D, Scheithauer W (1999) Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte-colony stimulating factor. Breast Cancer Res Treat 55:203-211
19. Nicolaides C, Dimopoulos MA, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N (2000) Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the hellenic Cooperative Oncology Group. Ann Oncol 11:873-875
20. Valenza R, Leonardi V, Gebbia V, Agostara B (2000) Gemcitabine and vinorelbine in pretreated advanced breast cancer. A pilot study. Ann Oncol 11:495-496
21. Hortobagyi G (2001) Treatment of advanced breast cancer with gemcitabine and vinorelbine. Oncology (Huntingt) 15 [Suppl 3]:15-17
22. Mariani G, Tagliabue P, Zucchinelli P, Brambilla C, Demicheli R, Villa E, Marchiaro A, Valagussa P, Bonadonna G, Gianni L (2001) Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast Cancer Res Treat 70:163-169
23. Stathopoulos GP, Rigatos SK, Pergantas N, Tsavdarides D, Athanasiadis I, Malamos NA, Stathopoulos JG (2002) Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J Clin Oncol 20:37-41
24. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
25. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
26. Porkka K, Blomqvist C, Rissanen P, Elomea I, Pyrhonen S (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. J Clin Oncol 12:1639-1647
27. Buzdar AU, Asmar L, Hortobagyi GN (1997) Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer 33 [Suppl 7]:S3-S6
28. Berruti A, Sperone P, Bottini A, Gorzegno G, Lorusso V, Brunelli A, Botta M, Tampellini M, Donadio M, Mancarella S, De Lena M, Alquati P, Dogliotti L (2000) Phase II study of vinorelbine with protracted fluorouracil infusion as a secondor third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 18:3370-3377